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Summary: External quality assessment programmes for specific IgE have been organised for some years in the
United Kingdom, Belgium and the Netherlands but independently. This paper describes a co-operation scheine
whereby the same samples were circulated simultaneously from each of the three countries and subsequent results
combined to produce a single "EURO EQAS" report.
Serum pools were prepared each containing antibodies, at differing concentrations, to 4 different allergens. The
allergens surveyed represented the 10 most commonly encountered in Northern Europe.
Results were submitted in grades (or classes) and in quantitative units and they showed some similarity by grade
regardless of method used but differed greatly in units probably due to method differences.
This paper shows how results could be treated to produce statistical data for the participants to help them be aware
of their performance internally and also in comparison to other users.
Introduction ment schemes. The good inter-assay and inter-laboratory
agreement of total serum IgE measurements indicates
In 1967, IgE was defined äs a fifth distinct human im- ^ ̂  measurement does not present a major technical
munoglobulin and it was shown to be the reaginic anti- challenge to regulated diagnostic allergy laboratories
body (l, 2). Shortly thereafter, serological assays were and therefore discussion of quality assurance schemes
developed to quantify the total leVel of IgE and to detect for ^ analyte wiu be excluded in this papen Rathei.
the presence of allergen-specific IgE antibodies in serum Ae emphasis of this overview will be on quality assur-
(3). Today, diagnostic laboratories throughout the world ance schemes that evaluate the results from laboratories
analyseserafromindividualssuspectedofhavingätopic that perform allergen specific IgE antibody measure-
disease using a spectrum of immunochemical reagents ments using a variety of serological immunoassays. The
and a variety of isotopic and non-isötopic immunoassays goai of this report is to describe the results produced by
(4, 5). The commercially available immunoassays for to- laboratories in the United Kingdom, Belgium and the
tal serum IgE have reached a high level of agreement Netherlands where a co-operative EURO EQAS is cur-
between methods and laboratories accordiiig to past rently in Operation. Problems associated with the arbi-
quality assurance schemes: this is primarily due to the trary nature of IgE antibody assay reporting methods
availability of well cha!racterised anti^human IgE re- that ultimately prevent effective inter-assay comparisons
agents, internationally recognised human IgE reference will be highlighted. The programme will be examined
preparations and widely used exteraal quality assess- within the context of repräsentative results generated by
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participants of the surveys during the 1992 cycle of dis-
tributions.
Allergen-Spccific IgE Immunoassay Methods
Commercially available allergen specific IgE antibody immuno-
assays are in a state of constant transition äs a result of continual
improvements in reagent quality, assay design and automated In-
strumentation. The earliest semi-quantitative non-competitive bind-
ing solid phase immunoradiometric assay for IgE antibody was
a procedure called the radioallergosorbent test or RAST. Second
generation assays have been providing laboratories with less lab-
our-intensive procedures that are more automated, non-isotopic and
that use microprocessor-driven Instruments. Despite the changes in
reagents and Instrumentation the majority of available commercial
allergen-specific IgE assays are considered highly complex assays
that require skilled technical staff.
IgE antibody immunoassays may be viewed simplistically äs being
composed of two major attributes. The first and generally less
problematic characteristic of IgE antibody assays is their ability to
detect nanogram quantities of IgE, often in the presence of micro-
gram quantities of other immunoglobulins (e. g. IgG) and while
this has posed a substantial challenge the analytical sensitivity of
most immunoassays today are able to cope with this pröbleni. The
second and more variable characteristic of these assays relates to
the allergen specificity of the antibody detected in the assay äs
humans can exhibit immediate-type hypersensitivity to over 300
naturally occurring substances that are extractable from the pollens
of trees, grasses and weeds and components released from animals,
moulds, insects and foods.
The same crude allergen-containing raw material can be processed
differently by two manufacturers, yielding allergen-containing as-
say reagents that vary widely in their allergenic potency and speci-
ficity. The allergen component of the assay must therefore be con-
sidered that reagent that produces the greatest variability in IgE
antibody measurements obtained with different commercially
available methods.
The overall performance of a particular laboratory in the exteraal
quality assurance schemes discussed subsequently depends on mul-
tiple inter-related variables. Besides the quality of the immuno-
assay (reagents and procedures) themselves, other important vari-
ables include the technical capability of the staff, intemal quality
control procedures and uncontrolled random errors that can occur
during the analysis. If a laboratory is out of control or it produces
IgE antibody results that do not agree with those produced by other
laboratories using the same method, then the assay and these other
associated variables need to be examined to identify the problem.
Aims of the Euro EQAS for Allergen Specific IgE Antibody
Assays
The aims of the external quality assessment schemes in each of the
three countries were similar but it was feit that ä co^operative
scheme could have many advantages. It was hoped to involve a
maximal number of laboratories that are performing specific IgE
immunoassays regardless of the size of the laboratory or their me-
thod in use. Also the improved size of the database would help
useful analysis of data for those laboratories using the less populär
commercial methods. As of 1992 the EuroEQAS had 221 partici-
pants growing to 239 by the end of the year (the number of partici-
pants and the methods in use can be seen in table 1).
This scheme collates qualitative "grade or class" and semiquantit-
ative "unit" measurements that reflect the presence and relative
amount of IgE antibody in a particular serum specimen. Differ.
ences in the results produced by a single laboratory can be com-
pared to a "group mean" produced by participants using the same
method. In this scheme differences in specific IgE antibody results













































































Total 68 72 86 86 62 72
for a partieular method are examined between countries and within
a laboratory by analysis of the same specimen up to 4 times within
a year. The ultimate goal of this scherne is to promote agreement
or unanimity of group results such that the majority of laboratories
performing a particular allergen specificity/assay eombination
agree that a specimen either does or does not contain specific IgE
antibody (and also ifpossible. agree on the relative "concentration"
of a particular IgE antibody). The quality assessment attempts to
use the Information to identify problem assays and laboratories and
remains flexible in order to modify the scheme design in order to
improve both inter-rnethod and inter^läboratory ständardisätion.
In all specific IgE antibody assays ä class 0 is defmed äs the ab-
sence of specific IgE antibody in the serum whilst classes l through
6 show increasing concentrations of the specific IgE antibody and
they have been shown to be associated with increasing clinical
sensitivity to the allergen in questipn.
In this quality assurance scheme it has been diffieult to evaluate
laboratory performance with IgE antibody results in class data ex-
cept in a gross manner. Borderline results are diffieult to Interpret
except when the serum specimen is known to have no IgE antibody
to that allergen specificity. Information about the performance of
the laboratory and the assay method that it uses in detecting a
spectrum of low to high levels in IgE antibody positive specimens
can be lost when the scheme uses only class scoring analysis. Most
IgE antibody assays also provide a more quantitative unitage as-
signment of IgE antibody which is based on total serum IgE or an
allergen specific antibody reference curve that has been constructed
with a calibration serum assigned an arbitrary number of "units".
IgE antibody levels in test specimens can then be reported in the
same "units" interpolated from this reference cürve. At preserit'the
quantitative relationship between the arbitrary units used by the
various commercial assays is not known. Thus, cornparisons of the
levels of IgE antibody reported by the participants in units using a
variety of commercial methods can be viewed only within a me-
thod group and not between method groups.
Survey Design and Sample Specifications
Four serum pools containing prescribed specific IgE antibodies
were prepared at the serum bank of Pharmacia (Uppsala, Sweden)
and each poql contained specific antibodies to four different aller-
gens at varying coneentration levefs. In addition each pool was
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ascribed a "negative allergen" one which the pool was known not
to contain (see tab. 2).
Three samples were distributed every 6 weeks by the national
scheme organisers and the participants were asked to test against
three named allergens in each sample and participants had to report
their results within 5 weeks. This randomised sampling enabled the
identity of each pool to be kept secret from the participants on
receipt of their samples.
Over the period of 1992 eight distributions were undertaken and
each pool was circtilated on 6 occasions and each allergen in each
pool was tested either 3 or 4 times.
Results from each participant were sent in the flrst instance to their
national organiser who issued national reports only within their
country and then all results were sent to the EURO organiser who
is based in the UK and then a EURO report was issued to all par-
ticipants.
The allergens chosen for analysis represented a cross-section of the
10 or so most common allergens in Western Europe and the most
common allergens were represented in more than one serum pool
at varying concentrations of IgE antibody level. The scheme was
anonymous in that each participant was identifled by a number
with no organiser knowing the identity of all the participants in
the scheme.
Data Analysis and Calculations
Results were analysed by sample number and by individual aller-
gens within a sample. As mentioned earlier results were analysed
by class or grade and by units and divided by method.
Results by grade were analysed äs an overall group and then by
method so that participants could see these results äs the number
of participants reporting each grade äs a group and also by method.
Results in units were analysed using the variance index scoring
System (described fully by Bullock & Wilde (6)) using the group
laboratory trimmed mean äs the designated value for each allergen-
specific antibody.
For each allergen-specific antibody a bias index score is calculated
for each laboratory and this is used to calculate the mean running
variance index score for each allergen specific antibody and overall
mean running index score which represents an overall performance













































criteria for each laboratory (for a complete explanation of data
analysis and statistical calculation see tab. 3).
Results
(a) By grades
The results in grades for each allergen-specific antibody
in each of the 4 pools circulated are shown in table 4
and they show that in the majority of cases almost all
the laboratories were able to identify those allergens pre-
sent and those absent in the 4 serum pools. The Pharma-
cia CAP method in the main reported higher grades to
each allergen compared to the Pharmacia RAST and
other methods in use but in some of the allergens a low
concentration of antibody did result in some methods
Tab. 3 Variance index scoring System.
The variance index scoring System gives a simple but reliable indi-
cation of laboratory performance which has proved robust over
many years of use. The System depends on a number of related
indices which are defmed äs follows:
Variance index (VI): The difference, irrespective of sign, between
the result returned and the designated value (DV), expressed äs a
percentage of the designated value, divided by the chosen coeffi-




Variance index score: For values of variance index less than 400,
variance index score = variance index. The maximum variance
index is 400, for all values of variance index greater than 400,
variance index score = 400.
Mean running variance index score: The mean of the variance in-
dex scores in the current analytical time window (for most analytes
this will be the last 4 results).
Bias index score: Identical to the variance index score but retaining
the sign; a result higher than the designated value will give a posi-
tive bias index score, whilst a lower result will give a negative bias
index score.
Mean running bias index score: The arithmetic mean of the bias
index scores in the current analytical time window.
Standard deviation ofthe bias index score: The Standard deviation
(SD) ofthe bias index scores in the current analytical time window.
Designated value: For this scheme and analytes this is the method
laboratory trimmed mean.
All laboratory trimmed mean: The recalculated mean value after
exclusion of all results outside 3 SD from the all trimmed labora-
tory mean. In this scheme the trimming is perfonned at the 7.5th
and 92.5th centiles.
Chosen coefficients of Variation: A scaling factor for each analyte
to correct for the current state of the art so äs to produce variance
index scores in a "common currency". The chosen coefficient of
Variation does not represent a "clinically acccptable error".
Overall mean ninning variance index score: The mean of the 24
most recent variance index scores irrespective of analyte for each
laboratory (minimum of 12 results required for calculation).
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reporting a grade 0 or l whilst other methods reported
a grade 2 or higher.
A point showing a difference of allergen recognition was
shown in the results to "house dust inite" present in
pools SP01 and SP04 where Pharmacia CAP users re-
port positive grades in both pools but DPC users report
positive grades in pool SP01 but negative grades in pool
SP04 (tab. 5).
(b) By units
A particular laboratories performance can in theory be
more rigorously evaluated with unit results interpolated
from a reference curve than with qualitative grade score
results but at present there are no internationally recog-
nised IgE antibody Standards that have been calibrated
for any allergen specificity. It is therefore not possible
to determine a "true value" for any serum specimen and
to permit the assessment of analytical sensitivities of the
various assays.
Therefore at the present time we are limited to an assess-
ment of a laboratories performance using a comparison
of results by those laboratories using the same method
and hence a designated value; of the "method mean" is
used for eaeh method. Despite the great Variation in re-
Eur. J. Clin, Ghem. Clin. Biochem. / Vol. 32,1994 / No. 6
Fifield et al.: External quality assessment: Spccific IgE antibodies 469
Tab. 5 Results in grades to Dl in two serum pools by method
and for two distribution numbers.
Melhod n 0 1 2 3 4
a) Serum pool SP01; distribution no. 6
All 201 48 35 114 4 0
Bioline 3 3 0 0 0 0
D P C 1 3 0 2 9 2 0
Others 1 5 1 0 2 3 0 0
CAP 98 2 0 94 2 0
RAST 5 8 2 9 2 7 2 0 0
Ventrex 4 1 2 1 0 0
b) Serum pool SP04; distribution no. 13
All 169 16 125 125 4 2
Bioline 3 3 0 0 0 0
D P C 1 0 2 5 2 1 0
Others 1 1 5 4 2 0 0
CAP 88 2 0 82 3 1





i sults between methods the stability of the all laboratory
1 trimmed mean for every allergen demonstrated the stab-
ility of the pools over the period of distributions. Within
each method the Pharmacia CAP System exhibited the
lowest coefficients of Variation (CV) for any allergen
compared to the other methods; this may be due in some
part to this method having the greatest number of users
or it beiüg the most precise method?
Class of performance Mean running variance index score
Good <100
Aveniap 1 9 Oft
Acceptable 201-300
Unacceptable >300
Table 7 shows mean running variance index scores div-
ided into the above categories and by country for all the
allergen specificities circulated during 1992.
With a chosen coefFicient of Variation of 15% for aller-
gen specificities it was heartening to see the majority of
laboratories with mean running variance index scores of
< 200 for all allergens. As a measure of overall analyti-
cal performance overall mean running variance index
score was used with a "moving window" of the last 24
results regardless of allergen specificity and again äs
with mean running variance index score it was decided
to classify performance in just the same way and table
8 shows the number of laboratories in each classification
and then divided by country. More than 70% of partici-
pants had overall mean running variance index scores of
< 200 with little difference by country: with this method
of "scoring" only being started in 1992 it is a little early




Although the numerical results for each method vary it
was hoped that a comparisön could be done using a
weighting factor but is was then obvious that the dose
responses between allergen specificities differed be-
tween methods. This problem can be shown by compar-
ing the ratio of results using method mean values for the
different allergen specificities expressed äs a ratio of two
methods (see tab. 6).
Results in units varied greatly between the methods in
use, so the all laboratory trimmed mean was not used to
evaluate performance criteria and also because of the
differences in results between allergens it was necessary
to assess laboratory performance by allergen. Therefore
the variance index scoring system was to be used based
on a designated value for each method, for results to
each allergen in each serum pool. A mean running vari-
ance index: score was calculated for each allergen speci-
ficity for each laboratory based on the last 4 results a
laboratory returned to that allergen - henee it portrayed
a "moving window" performance. A classification of
performance based on arbitrary Separation of mean run-
ning variance index scores was established äs fol-
lows:
Eur. J. Clin. Chem. Clin. Biochem. / Vol, 32,1994 / No. 6
Although EQA schemes for specific IgE have been or-
ganised in each of the three participating countries (UK,
Belgium and the Netherlands) for a number of years
very successfully they all feit that an expansion into a
"Euro scheine" would be beneficial for the participants
and also in terms of the expanded database.
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Hence 1992 saw the launch of a joint co-operation
scheme with common serum pools, common distribution
and reporting dates and a common Euro report. This was
made possible by maintaining the national identity and
Organisation of each scheme and also excellent co-oper-
in the Organisation and administration by the three
national organisers.
The choice of specific IgE antibodies to test against was
restricted in the first instance to the 8—10 most common
allergens occurring in Western Europe and the choice
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 32, 1994 /Nq. 6
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was borae out by the good analysis frequency of almost
all the allergens in circulation; the exception being the
mould Aliernaria (M6) which was analysed by much
fewer of the participants than M3 or the other allergens.
The scheme äs a whole has been enthusiastically re-
ceived (even äs a subscription-based scheme) and has
shown an increase in membership from 1992 to the be-
ginning of 1993 for all three countries. We are currently
exploring the possibility of inviting further countries in
Western Europe to participate — the advantage of this
scheme over others is that it is open to all types of
laboratories regardless of the metfaod of analysis they
use.
One of the advantages of a Euro scheme over a national
one was thought to be the greater database of lesser
known methods but we found a movement towards
greater use of the Pharmacia CAP method during the
year and thus the number of participants using some of
the other commercial methods is still very small (i. e.
< 5 or 6 users). Specific IgE analysis is in reality a
multi-analyte System where the antibodies to each differ-
ent allergen should be considered äs separate analytes
despite some common features such äs solid phase and
2nd antibody and because of this the EQ A scheme is far
more complex than thät of other analytes and schemes.
Thus analysis of overall results should be treated with
great caution.
The purification of allergens and preparation of protein
extracts can vary between different commercial sup-
pliers and then the types of solid phases for the binding
of these extracts are also very varied between manufac-
turers. These variations coupled with differences in anti-
body production arid lack of international reference
material makes the assay of specific IgE antibodies very
complex and thus the use of EQA results in defining
assay performance is just äs complex.
Because of these problems the first major criteria in data
analysis and performance criteria was to decide to use
method related niean results äs the designated values for
variance index score calculations. Thus all laboratories
would be compared to the designated values for their
method for all allergens being tested and therefqre a per-
formance criteria could be set for eäch method group.
Comparisons between methods should be treated with
caution äs they would depend on whether an allergen
was "recognised" äs positive or negative similarly by all
methods. Sadly for the time being this scheme is reälly
unable to directly compare results in any way between
manufacturers and' even between different methods from
the same manufacturer. This pröblem is aptly shown by
comparing the responses to "hoüse dust mite" by the
Pharmacia CAP and1 DPC Alastat methods in serum
pools SP01 and SP04. The usefulness in examining re-
sults by grades or classes and units is leading to the
belief that clinical performance criteria could be estab-
lished using a consensus result in grades and results in
units whilst not comparable between methods could be
used to calculate mean running variance index score and
overall mean running variance index score which are a
measure of analytical performance.
Conclusions and Future
1) Interest in an external quality assessment scheme or-
ganised on a multi-national basis is gaining with in-
creases in membership within each of the three partici-
pating countries.
2) There is a need to enlarge our result database by
country and by method (especially methods with cur-
rently small numbers of users).
3) The ränge of allergens used for testing is still to be
restricted to the 8— 10 most commonly requested aller-
gens in Western Europe.
4) It was also considered usefiil to test against 2— 3 of
the most common allergens at more than one antibody
concentration.
5) It appears a usefiil experiment to add recovery experi-
ments to allergens such äs Dl, El or T3 using a serum
pool diluted to 3 or 4 antibody concentration levels.
6) We will continue to use äs the designated value for
any result the method related trimmed mean because of
the great Variation in results between methods.
7) Progress will be made in separating criteria of per-
formance into clinical and analytical whereby clinical
performance by judged by the results in grades and ana-
lytical performance by the results in units.
8) Mean running variance index score and overall mean
running variance index score will continue to be used to
compare the performance of laboratories analytical re-
sults in
9) It may be necessary to install different chosen coef-
ficient of Variation for each allergen depending on the
quality and Variation of results between allergens.
10) Changes in the data handling of results to grass and
tree pollens may be necessary to separate results to
mixed and single allergens.
11) It is hoped that by speedier transference of data i t
will be possible to issue regulär reports to participants
quicker than at present.
12) Attempts to help improve standardisation and har-
monisation of specific IgE assays will be continued.
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